Systemic light chain (AL) amyloidosis is caused by abnormal plasma cell clones producing amyloidogenic light chains. The standard treatment is therefore chemotherapy targeting these clones, however, some patients are ineligible due to liver dysfunction. For these patients, preceding liver transplantation (LT) and following chemotherapy is a possible treatment option. We herein report a 58-year-old man with advanced hepatic AL amyloidosis who was successfully treated using this strategy. Previously reported cases treated with LT for this condition were reviewed, however, the outcomes were not favorable. We additionally investigated potential prognostic factors of this treatment approach to improve the outcome of these patients.
Introduction
Systemic light chain (AL) amyloidosis is caused by abnormal plasma cell clones in the bone marrow, which produce amyloidogenic immunoglobulin light chains, resulting in diffuse amyloid deposition and potentially fatal functional damage in multiple vital organs (1, 2) . The standard treatment involves chemotherapy with or without stem cell transplantation support, targeting the abnormal plasma cells (3) . A better prognosis can be expected if a sufficient reduction of amyloid precursor protein (involved serum free light chain, FLC) is achieved (4) . However, advanced organ involvement, especially cardiac involvement, occasionally limits the indications for chemotherapy and results in a poor outcome (5) . We previously reported that the liver is the third most frequently affected organ after the kidney and heart in systemic AL amyloidosis (6) , and clinical problems due to hepatic involvement, such as liver dysfunction and/or hepatic rupture, occasionally prevent patients from receiving effective chemotherapy (7) . Therefore, liver transplantation (LT) has been applied in some patients with dominant hepatic amyloidosis as a potential therapeutic option. However, the treatment outcome was not favorable in most cases (8) (9) (10) (11) (12) (13) (14) (15) . Therefore, it is important to determine the potential prognostic factors of this treatment option to select good candidates, maintain an appropriate condition to receive LT and subsequent chemotherapy, and provide a better outcome. To the best of our knowledge, this is the first report to focus on this point. We herein report a systemic AL amyloidosis patient who presented with dominant hepatic involvement and was therefore contraindicated for chemotherapy. However, after living-donor LT, he received chemotherapy and achieved a good hematological response with a long survival. Previously reported cases of hepatic AL amyloidosis receiving LT are reviewed and potential prognostic factors are investigated.
A 56-year-old man developed mild liver dysfunction without any clinical symptoms detectable on a surveillance medical checkup. One year later, he was admitted to a local hospital due to steatorrhea and a fever. Several examinations revealed deteriorated liver dysfunction with marked hepatomegaly. Amyloid deposition in both upper and lower intestinal mucosae and an elevated plasma cell population in the bone marrow (12.6%) were detected, however, both serum and urine M-protein were negative. Under a suspicion of systemic AL amyloidosis, the patient was referred to another hospital for treatment, but was regarded to be ineligible. At 58 years of age, he visited our department for further examinations.
A physical examination revealed macroglossia, ascites, and hepatomegaly palpable for two fingerbreadths in the right hypochondriac region. Neither jaundice nor leg edema was evident. A neurological examination detected mild numbness in the distal extremities and slight hepatic encephalopathy (grade I). A laboratory examination indicated severe hepatic involvement [serum albumin (ALB) 2. . The population of plasma cells in bone marrow was elevated (10.8%), but there were no destructive bone lesions suggestive of multiple myeloma. Biopsied gastroduodenal tissue sections were immunohistochemically examined and amyloid deposits showed specific immunoreactivity with anti-Aκ antibody. According to these findings, a diagnosis of κ type systemic AL amyloidosis was made. Despite slight thickening of the intraventricular septum wall (IVS, 1.23 cm, normal <1.2) on an echocardiogram, cardiac involvement was not included in the diagnosis because of the well-preserved systolic functions (FS 43.96%, EF 75.4%) and lack of elevation of cardiac biomarkers [N-terminal prohormone of brain natriuretic peptide (NT-pro BNP) 82.3 pg/mL (normal <125.0), troponin T (TnT) 0.012 ng/mL (normal <0.090)]. A CT scan with and without enhancement revealed a markedly enlarged liver with patchy areas of low-density contrast, splenomegaly, and ascites ( Figure A and B) . A markedly swollen liver by applying pressure to the inferior vena cava was also demonstrated by enhanced MRI. The patient was considered to be ineligible for standard chemotherapeutic approaches due to progressed hepatic failure. To restore his liver function to a level that could tolerate chemotherapy, preceding LT was planned and he was transferred to the Japanese Red Cross Medical Center. A living-donor liver graft (434 g) was taken from his son's left lobe and used to replace the enlarged involved liver weighing 3,100 g. There were no severe adverse events during the operation. Extensive AL κ amyloid deposition was histologically confirmed in the resected liver ( Figure D) . After several cycles of corticosteroid pulse therapy and an increased oral tacrolimus dose for mild acute rejection, slowly progressive renal dysfunction was noted and tacrolimus-related renal toxicity was suspected. He was then readmitted to our department. Six months after transplantation, two cycles of high-dose dexamethasone therapy (HDD, 40 mg on days 1-4 every 4 weeks) was introduced, and a partial response (serum FLC κ decreased from 245 to 69 mg/dL) was achieved. His renal function showed further deterioration even after switching from tacrolimus to cyclosporine. A renal biopsy was performed and amyloid pathology with dominant deposition in the medullary interstitium, but less in glomeruli, was observed. After initiating regular hemodialysis, additional chemotherapy using bortezomib and dexamethasone (BD, 1 mg/ m 2 subcutaneous bortezomib on days 1, 4, 8, and 11, and 40 mg of dexamethasone on days 1-4 every 3 weeks) was applied, and he finally achieved a very good partial response (VGPR) with a reduced serum FLC κ level (26.3 mg/dL) after four cycles of treatment. His cardiac function was well preserved throughout these treatment courses. The patient returned to work 3 months after discharge and has maintained a good general condition without any graft-related problems ( Figure C) or progression of amyloidosis during the observation period of 26 months after LT.
Discussion
Systemic AL amyloidosis is essentially a progressive fatal disease with a short median survival of 13.2 months in the absence of therapeutic intervention (2) . Therefore, the loss of eligibility for chemotherapeutic treatment indicates eventual death of the patient with disease progression. A group of patients with dominant hepatic AL amyloid involvement, referred to as primary hepatic amyloidosis, is very difficult to treat if liver dysfunction is too severe to allow the administration of chemotherapeutic agents. The median survival of patients with biopsy-proven hepatic involvement and ineligible for standard treatment was reported to be 8.5 months (16) . However, in patients eligible for standard chemotherapy and achieving a good hematological response better than a partial response, a long median survival >48 months can be expected, regardless of hepatic involvement (4). Therefore, LT may be one treatment option for these patients. To the best of our knowledge, there have been 15 previously reported cases of hepatic AL amyloidosis receiving LT (8) (9) (10) (11) (12) (13) (14) (15) . The clinical backgrounds of these cases, including our case, are summarized in Table 1 .
The outcome of this treatment approach is not sufficiently favorable. The median survival of patients in this study was 11 months, which was much shorter than that of patients eligible for standard chemotherapy mentioned above. Eventual death was reported in nine patients (56%), and only eight patients (50%) survived for more than 12 months after LT. To detect potential prognostic factors, the patients were divided into two groups according to their outcome at 12 months after LT and their clinical and laboratory data backgrounds were compared (Table 2) .
There were no significant differences in the patients' age, sex, or AL amyloid subtype between the groups. Visceral organ involvement, especially cardiac involvement, is critically important to determine the prognosis of AL patients (2) . The number of patients with cardiac involvement in the group with a poor prognosis (4 of 8) was double that in the group with a better prognosis (2 of 8). At least half of the patients with cardiac involvement in the poor prognosis group (2 of 4) were reported to have died due to cardiac problems (detailed causes of death were not described for the remaining two patients). However, the difference was not significant (p =0.304), likely due to the small study population. Other organ involvements, including renal involvement, were not significant.
Bilirubin is the most important prognostic factor of patients with hepatic involvement (16) . Therefore, serum ALB, Cr, and hepatic markers, including T-bil, at the time of LT were examined, however, a statistical analysis was not applicable due to the lack of data. Recent advances in AL amyloidosis research have detected new prognostic biomarkers, such as NT-pro BNP and TnT, related to the severity of cardiac amyloidosis, and differences between involved and uninvolved FLC (dFLC), which are sensitive for determining the patients' outcome (17) . Therefore, it is reasonable to postulate that these biomarkers may also be useful to predict the prognosis of hepatic amyloidosis in patients with or without LT. However, similar to the other biomarkers mentioned above, a statistical analysis was not possible due to an insufficient data set. It is strongly recommended for clinicians to learn how to examine amyloidosis patients with he- patic and possible other organ involvements in an appropriate and updated manner (18) .
The diagnosis of amyloidosis was not yet made in two cases at the time of LT. This factor was not a significant predictor in this study. However, as systemic deposition of amyloid can be the cause of unexpected organ dysfunction and possible death (14) , it is necessary to be aware of the possibility of amyloidosis in patients with undefined hepatic dysfunction.
Due to a shortage of cadaveric donors, living-donor partial liver transplantation (LDLT) is much more common than cadaveric liver transplantation in Japan. However, there is insufficient time for us to wait for cadaveric donor grafts for patients with hepatic amyloidosis due to the possibility of fatal progression within a few months following the appearance of liver dysfunction with hyperbilirubinemia (16) . Four patients, including our patient, received LDLT. Despite the more complicated operative procedure and a smaller volume of the donor liver graft (19) , the living-donor approach did not affect the outcome in this study. Pre-LT chemotherapy and perioperative complication(s) were not significant predictors of the outcome.
Considering the essentially progressive nature of systemic AL amyloidosis, it is reasonable that post-LT chemotherapy, which may halt or decelerate the disease progression, was a significant prognostic factor in the present study (p=0.020, Table 2 ). Hence, the most important point to consider for clinicians treating AL patients awaiting LT is to maintain their eligibility for curative chemotherapy. The eligibility criteria of chemotherapy vary among institutions and chemotherapy regimens, however, a preserved cardiac function (including lower New York Heart Association (NYHA) stage and lower cardiac biomarkers) is universally required (5) . In fact, the present cases in the poor prognosis group were prevented from receiving chemotherapy by their poor general condition due to extrahepatic amyloid involvement, mainly including cardiac involvement (12, 14, Table 1 ). Therefore, careful attention to cardiac involvement is required when treating patients with hepatic amyloidosis at the time of diagnosis, during the perioperative period of LT, and when initiating chemotherapy.
In conclusion, we presented another example of a primary hepatic amyloidosis patient who was successfully treated by LDLT and subsequent chemotherapy. To improve the outcome of this treatment strategy, a careful evaluation of visceral organ involvement, especially cardiac involvement, is required to maintain the patients' eligibility for chemotherapeutic treatment.
